FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309189397> ?p ?o ?g. }

• W4309189397 endingPage "A042" @default.
• W4309189397 startingPage "A042" @default.
• W4309189397 abstract "Abstract Background: There is an urgent need to understand why patients with clinically and histologically identical pancreatic ductal adenocarcinomas (PDACs) differ in response to treatment, disease progression, and survival. Although two standard chemotherapies are available, predictive biomarkers to guide regimen selection have not been defined. We previously reported that keratin 17 (K17) expression is a hallmark of PDAC cases with shortest patient survival. Furthermore, K17, explored using in vitro and in vivo murine models, drives resistance to gemcitabine and 5-fluorouracil, the most common chemotherapeutic agents in the two chemotherapies. Here, we aimed to validate the prognostic value of K17 and to further explore its role as a predictive biomarker. Methods: We used a cohort of 305 cases, with localized disease and who had gone tumor resection. An indirect immunoperoxidase method was used to detect K17 expression on surgical specimens, as previously described. Survival was plotted using the Kaplan–Meier method and hazard ratios (HRs) were calculated using Cox proportional hazard regressions for both, overall survival (OS) and progression-free survival (PFS). Results: Patients in the high-K17 expression group had shorter overall survival [median=25 mo., HR=1.511, p=0.0338] than those in the low-K17 expression group (median=42 mo.). In addition, high K17 expression was associated with shorter median OS (p=0.0280) and PFS (p=0.0434) in patients who were treated with gemcitabine (GEM) or with Gemcitabine/nab-Paclitaxel (GEMTAX) therapy (OS p=0.1959, PFS p=0.0724), compared to low-K17 counterparts. When we further separated our cohort by K17 level of expression and compared GEM and GEMTAX responses, we found that patients with tumors with high K17 expression do not benefit from GEMTAX adjuvant therapy (p=0.0356). Of note, K17 expression within the responder group was significantly lower than in tumors within the non-responder group for both Gem and GEMTAX (p&lt;0.001). Conclusions: K17 expression is confirmed as a robust prognostic biomarker, significantly correlated with poor OS and PFS in two independent cohorts of PDAC patients. More importantly, our results indicate that K17 expression predicts PDAC resistance to gemcitabine and poor response to GEMTAX. Collectively, our findings have implications could guide the development of K17 as a predictive biomarker for gemcitabine-based interventions in both adjuvant and palliative settings, to optimize therapeutic efficacy for PDAC. Citation Format: Lyanne Oblein, Lucia Roa-Peña, Sruthi Babu, Felicia D. Allard, Natalia D. Marchenko, Luisa F. Escobar-Hoyos, Kenneth R. Shroyer. Keratin 17 is a negative prognostic and predictive biomarker in pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A042." @default.
• W4309189397 created "2022-11-24" @default.
• W4309189397 creator A5009505699 @default.
• W4309189397 creator A5015447019 @default.
• W4309189397 creator A5023282465 @default.
• W4309189397 creator A5044442669 @default.
• W4309189397 creator A5049555015 @default.
• W4309189397 creator A5079259494 @default.
• W4309189397 creator A5086099448 @default.
• W4309189397 date "2022-11-15" @default.
• W4309189397 modified "2023-10-18" @default.
• W4309189397 title "Abstract A042: Keratin 17 is a negative prognostic and predictive biomarker in pancreatic ductal adenocarcinoma" @default.
• W4309189397 doi "https://doi.org/10.1158/1538-7445.panca22-a042" @default.
• W4309189397 hasPublicationYear "2022" @default.
• W4309189397 type Work @default.
• W4309189397 citedByCount "0" @default.
• W4309189397 crossrefType "journal-article" @default.
• W4309189397 hasAuthorship W4309189397A5009505699 @default.
• W4309189397 hasAuthorship W4309189397A5015447019 @default.
• W4309189397 hasAuthorship W4309189397A5023282465 @default.
• W4309189397 hasAuthorship W4309189397A5044442669 @default.
• W4309189397 hasAuthorship W4309189397A5049555015 @default.
• W4309189397 hasAuthorship W4309189397A5079259494 @default.
• W4309189397 hasAuthorship W4309189397A5086099448 @default.
• W4309189397 hasConcept C10515644 @default.
• W4309189397 hasConcept C126322002 @default.
• W4309189397 hasConcept C142724271 @default.
• W4309189397 hasConcept C143998085 @default.
• W4309189397 hasConcept C207103383 @default.
• W4309189397 hasConcept C2776694085 @default.
• W4309189397 hasConcept C2777292972 @default.
• W4309189397 hasConcept C2780258809 @default.
• W4309189397 hasConcept C2780739268 @default.
• W4309189397 hasConcept C2781197716 @default.
• W4309189397 hasConcept C2781413609 @default.
• W4309189397 hasConcept C44249647 @default.
• W4309189397 hasConcept C50382708 @default.
• W4309189397 hasConcept C55493867 @default.
• W4309189397 hasConcept C71924100 @default.
• W4309189397 hasConcept C72563966 @default.
• W4309189397 hasConcept C86803240 @default.
• W4309189397 hasConceptScore W4309189397C10515644 @default.
• W4309189397 hasConceptScore W4309189397C126322002 @default.
• W4309189397 hasConceptScore W4309189397C142724271 @default.
• W4309189397 hasConceptScore W4309189397C143998085 @default.
• W4309189397 hasConceptScore W4309189397C207103383 @default.
• W4309189397 hasConceptScore W4309189397C2776694085 @default.
• W4309189397 hasConceptScore W4309189397C2777292972 @default.
• W4309189397 hasConceptScore W4309189397C2780258809 @default.
• W4309189397 hasConceptScore W4309189397C2780739268 @default.
• W4309189397 hasConceptScore W4309189397C2781197716 @default.
• W4309189397 hasConceptScore W4309189397C2781413609 @default.
• W4309189397 hasConceptScore W4309189397C44249647 @default.
• W4309189397 hasConceptScore W4309189397C50382708 @default.
• W4309189397 hasConceptScore W4309189397C55493867 @default.
• W4309189397 hasConceptScore W4309189397C71924100 @default.
• W4309189397 hasConceptScore W4309189397C72563966 @default.
• W4309189397 hasConceptScore W4309189397C86803240 @default.
• W4309189397 hasIssue "22_Supplement" @default.
• W4309189397 hasLocation W43091893971 @default.
• W4309189397 hasOpenAccess W4309189397 @default.
• W4309189397 hasPrimaryLocation W43091893971 @default.
• W4309189397 hasRelatedWork W1991412268 @default.
• W4309189397 hasRelatedWork W2049717399 @default.
• W4309189397 hasRelatedWork W2071730404 @default.
• W4309189397 hasRelatedWork W2080607747 @default.
• W4309189397 hasRelatedWork W2085978374 @default.
• W4309189397 hasRelatedWork W2093872979 @default.
• W4309189397 hasRelatedWork W2151116649 @default.
• W4309189397 hasRelatedWork W2443311901 @default.
• W4309189397 hasRelatedWork W2462155706 @default.
• W4309189397 hasRelatedWork W4234982624 @default.
• W4309189397 hasVolume "82" @default.
• W4309189397 isParatext "false" @default.
• W4309189397 isRetracted "false" @default.
• W4309189397 workType "article" @default.